rifaximin IBS-D
Selected indexed studies
- Recent advances in the treatment of irritable bowel syndrome. (Pol Arch Intern Med, 2021) [PMID:34463082]
- Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. (Gut Microbes, 2022) [PMID:35014601]
- Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. (United European Gastroenterol J, 2022) [PMID:35695704]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). (2021) pubmed
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence. (2024) pubmed
- Recent advances in the treatment of irritable bowel syndrome. (2021) pubmed
- Novel Therapies in IBS-D Treatment. (2015) pubmed
- Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. (2022) pubmed
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. (2022) pubmed
- Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024. (2025) pubmed
- Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. (2022) pubmed
- Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial. (2024) pubmed
- Vitamin D Deficiency (VDD) and Benefits of Supplementation in Veterans with IBS-D. (2023) pubmed